G
Giacomo Allegrini
Researcher at University of Pisa
Publications - 87
Citations - 5250
Giacomo Allegrini is an academic researcher from University of Pisa. The author has contributed to research in topics: Irinotecan & FOLFOXIRI. The author has an hindex of 24, co-authored 81 publications receiving 4453 citations.
Papers
More filters
Journal ArticleDOI
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
Alfredo Falcone,Sergio Ricci,Isa Brunetti,Elisabetta Pfanner,Giacomo Allegrini,C. Barbara,Lucio Crinò,Giovanni Benedetti,W. Evangelista,Laura Fanchini,Enrico Cortesi,V. Picone,Stefano Vitello,Silvana Chiara,Cristina Granetto,Gianfranco Porcile,Luisa Fioretto,Cinzia Orlandini,Michele Andreuccetti,Gianluca Masi +19 more
TL;DR: The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics.
Journal ArticleDOI
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini,Fotios Loupakis,Carlotta Antoniotti,Cristiana Lupi,Elisa Sensi,Sara Lonardi,Silvia Mezi,Gianluca Tomasello,Monica Ronzoni,Alberto Zaniboni,Giuseppe Tonini,Chiara Carlomagno,Giacomo Allegrini,Silvana Chiara,Mauro D'Amico,Cristina Granetto,Marina Cazzaniga,Luca Boni,Gabriella Fontanini,Alfredo Falcone +19 more
TL;DR: An updated analysis of the TRIBE study aimed to provide mature results for overall survival-a secondary endpoint-and report treatment efficacy in RAS and BRAF molecular subgroups, and assessed the secondary endpoint of overall survival in the main cohort.
Journal ArticleDOI
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis,Chiara Cremolini,Gianluca Masi,Sara Lonardi,Vittorina Zagonel,Lisa Salvatore,Enrico Cortesi,Gianluca Tomasello,Monica Ronzoni,Rosella Spadi,Alberto Zaniboni,Giuseppe Tonini,Angela Buonadonna,Domenico Amoroso,Silvana Chiara,Chiara Carlomagno,Corrado Boni,Giacomo Allegrini,Luca Boni,Alfredo Falcone +19 more
TL;DR: FOLFOXIRI plus bevacizumab, as compared with FOLFIRI plus was improved the outcome in patients with metastatic colorectal cancer and increased the incidence of some adverse events.
Journal ArticleDOI
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini,Carlotta Antoniotti,Daniele Rossini,Sara Lonardi,Fotios Loupakis,Filippo Pietrantonio,Roberto Bordonaro,Tiziana Latiano,Emiliano Tamburini,Daniele Santini,Alessandro Passardi,Federica Marmorino,Roberta Grande,Giuseppe Aprile,Alberto Zaniboni,Sabina Murgioni,Cristina Granetto,Angela Buonadonna,Roberto Moretto,Salvatore Corallo,Stefano Cordio,Lorenzo Antonuzzo,Gianluca Tomasello,Gianluca Masi,Monica Ronzoni,Samantha Di Donato,Chiara Carlomagno,Matteo Clavarezza,Giuliana Ritorto,Andrea Mambrini,Mario Roselli,Samanta Cupini,Serafina Mammoliti,Elisabetta Fenocchio,Enrichetta Corgna,Vittorina Zagonel,Gabriella Fontanini,Clara Ugolini,Luca Boni,Alfredo Falcone,Filippo de Braud,Evaristo Maiello,Giovanni Luca Frassineti,Teresa Gamucci,Francesco Di Costanzo,Luca Gianni,Patrizia Racca,Giacomo Allegrini,Alberto Sobrero,Massimo Aglietta,Enrico Cortesi,Domenico Corsi,Alberto Ballestrero,Andrea Bonetti,Francesco Di Clemente,Enzo Maria Ruggeri,Fortunato Ciardiello,Marco Benasso,Stefano Vitello,Saverio Cinieri,Stefania Mosconi,Nicola Silvestris,Antonio Frassoldati,Samantha Cupini,Alessandro Bertolini,Giampaolo Tortora,Carmelo Bengala,Daris Ferrari,Antonia Ardizzoia,Carlo Milandri,Silvana Chiara,Gianpiero Romano,Stefania Miraglia,Laura Scaltriti,Francesca Pucci,Livio Blasi,Silvia Brugnatelli,Luisa Fioretto,A.S. Ribecco,Raffaella Longarini,Michela Frisinghelli,Maria Banzi +81 more
TL;DR: The triplet FOLFOXIRI showed improved outcomes for patients with metastatic colorectal cancer, compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab, but the actual benefit of the upfront exposure to the three cytotoxic drugs compared with a preplanned sequential strategy of doublets was not clear.
Journal ArticleDOI
Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis
Gianluca Masi,Enrico Vasile,Fotios Loupakis,Samanta Cupini,Lorenzo Fornaro,Giacomo Giulio Baldi,Lisa Salvatore,Chiara Cremolini,I. Stasi,Isa Brunetti,Maria Agnese Fabbri,Martina Puglisi,Patrizia Trenta,Cristina Granetto,Silvana Chiara,Luisa Fioretto,Giacomo Allegrini,Lucio Crinò,Michele Andreuccetti,Alfredo Falcone +19 more
TL;DR: Six months of induction chemotherapy with FOLFOXIRI is associated with a clinically significant improvement in the long-term outcome compared with F OLFIRI with an absolute benefit in survival at 5 years of 7%.